# OnCo record paper-maia-daratumumab-rd-nejm-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-maia-daratumumab-rd-nejm-2019" ;
  schema:name "MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant"@en ;
  schema:description "Adding the CD38 antibody daratumumab to standard lenalidomide-dexamethasone cut the risk of progression or death by about 44% in older myeloma patients, and later extended survival."@en ;
  schema:url <https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1817249>, <https://clinicaltrials.gov/study/NCT02252172> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1817249> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Facon T, Kumar S, Plesner T, et al." ;
  onco:related <https://onco.cc/key-papers/paper-cepheus-dara-vrd-natmed-2025/>, <https://onco.cc/pairings/cd38-plus-triplet/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:targets <https://onco.cc/targets/cd38/> ;
  onco:drugs <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/mrd-negativity-myeloma/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-aging-comorbidity/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:journals <https://onco.cc/journals/nejm/> .